The recent approvals and robust pipeline activity are expected to fuel the market of molecular glues in the 7MM during the forecast period 2025-2034 due to factors like improved diagnosis, treatment ...

New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025Upon FDA approval, ...

Capricor presented preclinical data at the 2024 American Association of Extracellular Vesicles (AAEV) Annual Meeting. The ...

BofA lowered the firm’s price target on United Therapeutics (UTHR) to $314 from $328 and keeps an Underperform rating on the shares. The firm ...

The partnership underscores Servier's commitment to developing targeted therapies that address unmet medical needs in oncology; Servier will develop and commercialize BDTX-4933, a ...

Q4 2024 Earnings Call Transcript March 17, 2025 Sangamo Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ ...

Shares of United Therapeutics Co. (NASDAQ:UTHR – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are covering the firm, MarketBeat reports.

Learn more about whether Exact Sciences Corporation or Amicus Therapeutics, Inc. is a better investment based on AAII's A+ ...

Regulatory and reimbursement pathways should consider indirect benefits in addition to direct health benefits when evaluating ...

U.S. Secretary of Agriculture Brooke Rollins recently announced a $1 billion-dollar comprehensive strategy to curb highly pathogenic avian influenza (HPAI), protect the U.S. poultry industry, and ...

Learn more about whether PTC Therapeutics, Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...